Role of Immunotherapy in the Treatment of Cancer: A Systematic Review
by
, , , , , ,
Sia Pei Ling
1
,
Long Chiau Ming
1,2
,
Jagjit Singh Dhaliwal
1,
Madhu Gupta
3,
Chrismawan Ardianto
2,*,
Khang Wen Goh
4,
Zahid Hussain
5 and
Naeem Shafqat
1,* 1
PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong BE1410, Brunei
2
Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia
3
School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 110017, India
4
Faculty of Data Science and Information Technology, INTI International University, Nilai 71800, Malaysia
5
Faculty of Health, University of Canberra, Bruce, ACT 2617, Australia
*
Authors to whom correspondence should be addressed.
Cancers 2022, 14(21), 5205; https://doi.org/10.3390/cancers14215205
Submission received: 26 August 2022
/
Revised: 14 October 2022
/
Accepted: 15 October 2022
/
Published: 24 October 2022
(This article belongs to the Special Issue Advances in Anticancer Drugs and Pharmacotherapy of Cancer)
Simple Summary
The main purpose of this article is to review the efficacy of immunotherapy either as a stand-alone treatment or in combination with the available conventional cancer treatment in stopping the reoccurrence of cancer. The article will assess and determine the efficacy of immunotherapy in the treatment of cancer via the overall survival and progression-free survival rate.
Abstract
Tremendous progress has been made in cancer research over the years, and, as a result, immunotherapy has emerged as an important therapy for the treatment of cancer, either as a stand-alone treatment or in conjunction with other cancer therapies. Immunotherapy has demonstrated encouraging outcomes and offers a viable strategy for not only enhancing the quality of life but also dramatically boosting the overall survival rate of cancer patients. The objective of this systematic review was to assess the efficacy of immunotherapy in the treatment of cancer. Databases such as PubMed and Science Direct were searched from their inception until September 2021, using the following keywords: cancer immunotherapy, cancer recurrence, cancer treatment options, and cancer therapies. The systematic review was conducted in accordance with the PRISMA protocol. There were a total of 599 articles; however, after applying the inclusion and exclusion criteria, the final review ended up with 34 publications. In conclusion, the studies have demonstrated that immunotherapy is a viable alternative treatment option for patients with recurrent or metastatic cancer, since the overall survival rate and progression-free survival rate were shown to be successful.
